Arch Virol 2016 May 10;161(5):1183-7. Epub 2016 Feb 10.
Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, 13164, Iran.
Download full-text PDF
J Med Virol 2015 Jul 13;87(7):1124-9. Epub 2015 Mar 13.
Department of Virology, Pasteur Institute of Iran, Tehran, Iran.
The human parvovirus B19 (B19) usually causes a subclinical infection in immunocompetent individuals. Whereas immunocompromised individuals such as patients infected with HIV are at risk of persistent anemia due to B19 infection. Only few studies have been carried out on distribution and molecular epidemiology of B19 in Iran. Read More
Clin Infect Dis 1995 Jan;20(1):170-3
Department of Medicine, Hospital of the University of Pennsylvania.
Parvovirus B19 has been described as a cause of chronic anemia in immunosuppressed patients, including those infected with human immunodeficiency virus (HIV). In this study serological assays and the polymerase chain reaction (PCR) were used to establish the prevalence of both prior and active infection due to parvovirus B19 among a general population of 105 HIV-infected individuals (cohort I) and among 22 HIV-infected patients with anemia (cohort II). Eight individuals in cohort I (7. Read More
J Infect Dis 1994 Apr;169(4):938-40
AIDS Patient Care STDS 2000 Jan;14(1):7-11
Division of Hematology, Cook County Hospital and Rush Medical College, Chicago, Illinois 60612, USA.
Persistent infection with parvovirus B19 (B19) is an important treatable cause of anemia in HIV-infected patients. B19 has a tropism for erythroid progenitors and causes pure red cell aplasia (PRCA). The failure to produce neutralizing antibodies to the virus following B19 infection in immunodeficient persons may result in persistent viremia and chronic PRCA (B19-PRCA). Read More